Zentalis Pharmaceuticals’ (ZNTL) Buy Rating Reaffirmed at HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Monday, Marketbeat Ratings reports. They presently have a $10.00 price objective on the stock. HC Wainwright‘s target price points to a potential upside of 323.73% from the company’s current price.

ZNTL has been the topic of several other reports. William Blair started coverage on Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They issued an “outperform” rating on the stock. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Mizuho began coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock. Jefferies Financial Group upgraded shares of Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock traded down $0.03 on Monday, reaching $2.36. 1,206,983 shares of the stock were exchanged, compared to its average volume of 1,545,117. Zentalis Pharmaceuticals has a one year low of $1.21 and a one year high of $6.95. The stock has a market cap of $169.15 million, a PE ratio of -1.21 and a beta of 1.93. The stock has a 50 day moving average price of $3.23 and a 200 day moving average price of $3.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, research analysts expect that Zentalis Pharmaceuticals will post -2.11 earnings per share for the current fiscal year.

Insider Activity at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters bought 4,335,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were bought at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the completion of the transaction, the insider owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. This trade represents a 32.09% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ZNTL. Spark Investment Management LLC acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at $61,000. Susquehanna Fundamental Investments LLC acquired a new position in Zentalis Pharmaceuticals during the second quarter worth about $126,000. Stonepine Capital Management LLC acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $783,678. Seven Fleet Capital Management LP increased its holdings in shares of Zentalis Pharmaceuticals by 188.7% during the second quarter. Seven Fleet Capital Management LP now owns 317,600 shares of the company’s stock worth $1,451,000 after buying an additional 207,600 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter worth about $5,406,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.